Literature DB >> 2891583

Successful treatment of idiopathic secretory diarrhea of infancy with the somatostatin analogue SMS 201-995.

W Jaros1, J Biller, S Greer, T O'Dorisio, R Grand.   

Abstract

The somatostatin analogue SMS 201-995 has been reported to be effective in treating adult secretory diarrhea due to vasoactive intestinal polypeptidoma. We report the effectiveness of this drug in treating severe refractory secretory diarrhea of uncertain etiology in an infant. The patient developed diarrhea within the first few days of life, with mean stool output of 250 ml/kg.day (expected 10 ml/kg.day). Small bowel biopsy showed mild focal enteritis. Serum levels of known gastrointestinal secretagogues were normal. No tumor was detected. Diarrhea was not adequately controlled by various drug treatments. Addition of subcutaneous SMS 201-995 produced a significant sustained decrease in stool output to 80-100 ml/kg.day. During SMS 201-995 treatment, no metabolic, hormonal, or growth abnormalities were noted. SMS 201-995 was discontinued after 9 mo because of patient irritability. Stool output rose immediately to 173 ml/kg.day, and remained stable for 6 mo. It is concluded that SMS 201-995 was a safe and effective treatment in this single childhood case of severe idiopathic secretory diarrhea.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2891583     DOI: 10.1016/0016-5085(88)90629-4

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  8 in total

Review 1.  Clinical pharmacology and therapeutics.

Authors:  M J Kendall; R C Horton
Journal:  Postgrad Med J       Date:  1990-03       Impact factor: 2.401

2.  Modulation of fluid absorption and the secretory response of rat jejunum to cholera toxin by dietary fat.

Authors:  F A Sagher; J A Dodge; R Moore; C McMaster; G McCaughey
Journal:  Gut       Date:  1990-11       Impact factor: 23.059

3.  Effect of somatostatin analog (SMS 201-995) on in vivo intestinal fluid transport in rats. A limited systemic effect.

Authors:  R N Fedorak; S L Allen
Journal:  Dig Dis Sci       Date:  1989-04       Impact factor: 3.199

Review 4.  Clinical use of the long acting somatostatin analogue octreotide in pediatrics.

Authors:  M T Tauber; A G Harris; P Rochiccioli
Journal:  Eur J Pediatr       Date:  1994-05       Impact factor: 3.183

5.  Clinical response to the long acting somatostatin analogue SMS 201-995 in a child with congenital microvillus atrophy.

Authors:  R T Couper; A Berzen; G Berall; P M Sherman
Journal:  Gut       Date:  1989-07       Impact factor: 23.059

Review 6.  Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects.

Authors:  A G Harris
Journal:  Gut       Date:  1994       Impact factor: 23.059

Review 7.  Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.

Authors:  P E Battershill; S P Clissold
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

8.  Therapeutic applications of octreotide in pediatric patients.

Authors:  Abdulrahman Al-Hussaini; Decker Butzner
Journal:  Saudi J Gastroenterol       Date:  2012 Mar-Apr       Impact factor: 2.485

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.